Silence Therapeutics (LON:SLN) chief financial officer Rob Quinn and head of business development John Strafford discuss this week's 'transformational' deal they've struck with major AstraZeneca.
It's worth US$80mln in cash and investment upfront, plus a further US$400mln in milestone payments and royalties for each disease area targeted.
Using Silence’s small interfering RNA, or siRNA technology, AstraZeneca is looking to initially develop treatments for liver, heart and lung diseases.